Viracta Therapeutics, Inc.: Nasdaq/NYSE listing notice — Viracta receives Nasdaq minimum bid price deficiency notice; 180 days to cure

Viracta Therapeutics, Inc.

Nasdaq notified Viracta on Nov 15, 2023 that its common stock closing bid price was below $1.00 for 30 consecutive business days.
Company has until May 13, 2024 to regain compliance by closing at $1.00 or more for 10 consecutive business days.
If not compliant by May 13, Viracta may transfer to Nasdaq Capital Market and receive an additional 180-day cure period.
The deficiency notice has no immediate impact on trading; Viracta will monitor bid price and consider available remedies.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Viracta Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 15, 2023, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 c

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-064914

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.